| Ytd | -10.26% | |
| 1y | 33.27% |
| Open | 27.92 | Prev Close | 27.47 | Low | 27.33 | High | 28.00 | Mkt Cap | 16.97B |
| Vol | 1.44M | Avg Vol | 1.85M | EPS | 1.32 | P/E | 20.94 | Forward P/E | 15.10 |
| Beta | 0.68 | Short Ratio | 4.59 | Inst. Own | 13.57% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 26.18 | 200-d Avg | 29.22 | 1yr Est | 36.82 |
GMAB News
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 tria
Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label
AVAV: 31% | AeroVironment shares are trading higher after the company reported better-than-expected
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met th
Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combin
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and
Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act t
Results from the Phase 2 EPCORE DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrat
Genmab A/S (NASDAQ:GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal
Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street ana
ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse ev